Document is current
Any future updates will be listed below
-
Authors
Westerling, R.
Daryani, A.
Gershuni, O.
Czabanowska, K.
Brand, H.
Erdsiek, F.
Aksakal, T.
Uner, S.
Karadag Caman, O.
Ozcebe, H.
Brzoska, P. http://orcid.org/0000-0001-6489-5198
-
Funding
Funding for this research was provided by:
Erasmus+ (2015-1-TR01-KA204-022393)
- License Information
-
More Information
Article History
Received: 14 November 2019
Accepted: 15 October 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: The study was assessed and approved by ethical committees in each of the four countries, in accordance with the regulations in each respective country. In Germany, the study was reviewed by the Ethics Committee of the Faculty of Behavioral and Social Sciences of Chemnitz University of Technology. The review showed that there was no need for further evaluation of the study beyond this initial assessment by the Ethics Committee (No. V-144-AR-PB-Antibiotic-10,062,016). In the Netherlands, the study was reviewed and approved by the Medical Ethics Review Committee of Maastricht University and the University Medical Centre Maastricht (No.16–4-213.1/ab). In Sweden, the Regional Ethical Committee at Uppsala University assessed the study, stating that no further approval beyond that assessment would be needed or was applicable under Swedish law (No. 2016/377). In Turkey, the study was reviewed and approved by the Non-Interventional Clinical Research Ethics Board of Hacettepe University (No. GO 6/382–27).
: Not applicable.
: There are no financial or non-financial competing interests.
